Enliven Therapeutics, Inc. (ELVN) NASDAQ

19.75

-0.47(-2.32%)

Updated at August 18 04:00PM

Currency In USD

Valuation

Market Cap1.06B
Enterprise Value935.03M
P/E Ratio-10.27
PEG Ratio2.46
Price/Sales Ratio3,702.22
Price/Book Ratio2.11
Enterprise/Revenue3,324.25
Enterprise/EBITDA-9.21

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-317.14
Operating Margin-361.52

Management Effectiveness

Return On Assets-0.2
Return On Equity-0.29

Income Statement

Revenue0
Revenue/Share0.01
Gross Profit-317,000
EBITDA-88.48M
Net Income-89.02M
Diluted EPS-1.89

Balance Sheet

Total Cash490.5M
Total Cash/Share9.41
Total Debt0
Total Debt/Equity0
Current Ratio32.58
Book Value Per Share9.37

Price History

52-Week Change-16.06
52-Week High30.03
52-Week Low13.3
Moving Average 50 Days20.67
Moving Average 200 Days21.36

Statistics

Average Volume498,258
Shares Outstanding59.24M
% Held by Institutions100.06

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:4
Last Split DateFebruary 24, 2023